European Chemicals Agency
This article was originally published in The Rose Sheet
Executive Summary
Asked about industry's progress in relation to deadlines set by Registration, Evaluation and Authorization of Chemicals law, the European Chemicals Agency says visibility into the situation remains hazy. "We are trying to alert and remind everyone about their obligations, but we receive very limited feedback about how the processes are going in reality," the agency noted in an e-mail. "We may only make conclusions after the deadline in December 2010" (1"The Rose Sheet" Feb. 1, 2010). The 2010 deadline does not apply to all manufacturers and importers, but ECHA "takes very seriously" the challenges that may be faced by small and medium enterprises (SME) in preparing their registration dossiers. In addition to other awareness/education initiatives, ECHA has begun launching 2"Guidance in a Nutshell" documents "providing condensed and SME-friendly guidance with the aim of explaining, in simple terms, specific topics of particular relevance to the non-scientific reader." Meanwhile, core guidances are being published in 21 official European languages, ECHA says. According to the agency, general findings from more than 1,000 inspections carried out by national authorities will be announced by the end of the first quarter. Forthcoming document entitled "Minimum Criteria for REACH Inspections" will offer more detailed direction for inspectors, ECHA says
You may also be interested in...
ECHA Offers REACH Progress Report, Urging Registrants To Improve Dossiers
By the end of 2009, the European Chemicals Agency had completed 15 of 30 "compliance checks" initiated since registration dossiers started dribbling in under REACH, and almost half of its checks have inspired quality observation letters due to inadequacies, the agency says
European Chemicals Agency To Report On REACH Enforcement Project, Part 1
A report summarizing results from the first stage of the REACH enforcement project will be published this spring, according to the European Chemicals Agency
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”